GSVRX
Price
$16.41
Change
+$0.08 (+0.49%)
Updated
Jun 9 closing price
Net Assets
457.1M
RMFCX
Price
$62.18
Change
+$0.38 (+0.61%)
Updated
Jun 9 closing price
Net Assets
116.64B
Interact to see
Advertisement

GSVRX vs RMFCX

Header iconGSVRX vs RMFCX Comparison
Open Charts GSVRX vs RMFCXBanner chart's image
GSVRX vs RMFCX Comparison Chart in %
View a ticker or compare two or three
VS
GSVRX vs. RMFCX commentary
Jun 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSVRX is a Buy and RMFCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 117B vs. GSVRX (457M). RMFCX pays higher dividends than GSVRX: RMFCX (1.19) vs GSVRX (0.43). GSVRX was incepted earlier than RMFCX: GSVRX (19 years) vs RMFCX (24 years). GSVRX (1.49) is less costly to investors than RMFCX (0.91). GSVRX is a more actively managed with annual turnover of: 74.00 vs. RMFCX (30.00). GSVRX has a lower initial minimum investment than RMFCX: GSVRX (0) vs RMFCX (250). RMFCX annual gain was more profitable for investors over the last year : 9.32 vs. GSVRX (7.60). RMFCX return over 5 years is better than : 33.61 vs. GSVRX (0.93).
GSVRXRMFCXGSVRX / RMFCX
Total Expense Ratio1.250.91137%
Annual Report Gross Expense Ratio1.490.91164%
Fund Existence19 years24 years-
Gain YTD13.0896.016218%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets457M117B0%
Annual Yield % from dividends0.431.1936%
Returns for 1 year7.609.3282%
Returns for 3 years19.3734.4256%
Returns for 5 years0.9333.613%
Returns for 10 years18.2491.3420%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SBFG22.890.65
+2.92%
SB Financial Group
KRO6.530.02
+0.31%
Kronos Worldwide
BOX26.54-0.01
-0.04%
BOX
MTSI358.72-3.14
-0.87%
MACOM Technology Solutions Holdings
BOLT4.62-0.10
-2.12%
Bolt Biotherapeutics Inc